Article
A complex mutational signature generated by cytarabine resistance.
NAR cancer - 1 Sept 2026
Cao Dengchao, Yin Mianmian, Bertoli Ryan, Zhang Zhenhua, Lu Allyson, Zhu Jack, Baslan Timour, Chung Yang Jo, Negi Vijay, Meltzer Paul, Aplan Peter D
Abstract excerpt
T-cell acute lymphoblastic leukemia (T-ALL) patients generally respond well to chemotherapy, but T-ALL cells at relapse are typically resistant to chemotherapy. The specific mechanisms leading to chemoresistance are incompletely understood. We used Mcm2 hypomorph T-ALL cell lines, which are prone to copy number variant mutations, to identify acquired mutations that underlie chemoresistance. We found acquired copy...
Topics
Join the communities discussing this publication.